Role of Thoracic Radiotherapy Combined with Chemotherapy in Limited Stage Small Cell Lung Cancer (SCLC)

1990 ◽  
Vol 13 (4) ◽  
pp. 253-258 ◽  
Author(s):  
A. Kraft ◽  
H. Arnold ◽  
T. Zwingers ◽  
H. Bodemann ◽  
F.v. Bültzingslöwen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Limited Stage

scholarly journals Sequential chemotherapy followed by radical thoracic radiotherapy (50 Gy in 25 fractions) in limited stage small cell lung cancer

2020 ◽  
Vol 14 ◽  
Author(s):  
Muhammad Shahid Iqbal ◽  
Joseph Carlow ◽  
Fiona McDonald ◽  
Philip Atherton ◽  
Helen Turnbull ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Sequential Chemotherapy ◽  
Limited Stage

Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group.

1993 ◽  
Vol 11 (5) ◽  
pp. 879-884 ◽  
Author(s):  
D H Johnson ◽  
A T Turrisi ◽  
A Y Chang ◽  
R Blum ◽  
P Bonomi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pilot Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Eastern Cooperative Oncology Group ◽  
Small Cell ◽  
Induction Treatment ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Limited Stage

PURPOSE This pilot study was undertaken to determine the efficacy and feasibility of alternating cisplatin and etoposide with multiple daily fractions of thoracic radiotherapy (TRT) in patients with limited-stage small-cell lung cancer (SCLC). PATIENTS AND METHODS Thirty-four SCLC patients received four courses of cisplatin (30 mg/m2/d x 3) plus etoposide (120 mg/m2/d x 3) (PE) every 3 weeks. TRT was administered twice daily (1.5 Gy per fraction) for 5 consecutive days in the week after cycles 1, 2, and 3 of chemotherapy (total TRT dose, 45 Gy). Patients who achieved a complete response (CR) received one course of late-intensification (LI) treatment consisting of cyclophosphamide (4 g/m2) and etoposide (900 mg/m2). Prophylactic cranial irradiation (PCI) was optional. RESULTS Nineteen of 32 assessable patients achieved a CR (59%) and 12 had a partial response (38%), for an overall response rate of 97% (95% confidence interval [CI], 84% to 99%). Median survival was 18 months, while 2-year progression-free survival was 47%. Leukopenia < or = 1,000/microL occurred in 12% of induction treatment cycles. Severe esophagitis was uncommon. Pulmonary fibrosis that was asymptomatic or minimally symptomatic was observed in eight patients (25%). There was one episode of adult respiratory distress syndrome (ARDS) during LI chemotherapy. Life-threatening neutropenia (< or = 500/microL) developed in all patients who underwent LI chemotherapy, with a median duration of 10 days (range, 8 to 19). Two patients died of sepsis during LI chemotherapy. CONCLUSION Alternating PE and TRT as performed in this trial is an effective brief induction regimen for limited-stage SCLC. However, this particular regimen did not appear to be substantially different in terms of efficacy or toxicity compared with regimens using concurrent chemotherapy and standard-fraction TRT. LI chemotherapy was associated with unacceptable toxicity and did not appear to have a favorable impact on survival.

scholarly journals Optimal timing of thoracic radiotherapy in limited stage small cell lung cancer (SCLC) with daily fractionation: A brief report

2019 ◽  
Vol 132 ◽  
pp. 23-26 ◽  
Author(s):  
Shaakir Hasan ◽  
Richard White ◽  
Paul Renz ◽  
Stephen Abel ◽  
Zachary Otaibi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Optimal Timing ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Limited Stage
Sign in / Sign up

Export Citation Format

Share Document